Emcure Pharmaceuticals Quarterly Results for Trading Insights

In Sept 2025, Emcure Pharmaceuticals (EMCURE) reported revenue ₹2,273 Cr and net profit ₹251 Cr — revenue +11.5% YoY. For annual financials, live price and key ratios, visit Emcure Pharmaceuticals share price today.

Latest Quarter Net Profit
₹251 Cr
QSept 2025
Quarterly Results

EMCURE Quarterly Results — Revenue, Profit & EPS Highlights

Emcure Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with EMCURE fundamental valuation to assess whether the stock is under or overvalued.

  • Revenue of ₹2,273 Cr in Sept 2025 (+7.2% vs Mar 2025, +11.5% vs Sept 2024)
  • Net Profit of ₹251 Cr in Sept 2025 (+27.4% vs Mar 2025, +24.3% vs Sept 2024)
  • EBITDA of ₹479 Cr in Sept 2025 (+20.7% vs Mar 2025)
  • Operating Margin of 21.0% in Sept 2025 (+2.0pp vs Mar 2025)
  • Earnings Per Share of ₹12.85 in Sept 2025 (+28.9% vs Mar 2025)

Emcure Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

EMCURE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 QoQ YoY
Revenue (₹ Cr) 2,273 2,121 2,104 2,365 2,038 7.2% 11.5%
Net Profit (₹ Cr) 251 197 215 231 202 - -
EBITDA (₹ Cr) 479 397 417 456 417 - -
EPS (₹) 12.85 9.97 10.92 12.16 10.23 - -
Operating Margin (%) 21.0% 19.0% 20.0% 19.0% 19.0% - -

EMCURE Share Price Trend — 1-Year Movement Across Quarterly Results

Emcure Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse EMCURE ownership pattern to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin 11.0%
EBITDA Margin 21.1%
Operating Margin 21.0%
ROE (Annual) 21.6%

Balance Sheet Highlights

Total Assets ₹8,233 Cr
Total Equity ₹4,642 Cr
Current Assets ₹4,556 Cr
Current Liabilities ₹923 Cr

Cash Flow Analysis

Operating Cash Flow ₹852 Cr
Investing Cash Flow ₹-96 Cr
Financing Cash Flow ₹-814 Cr
Net Cash Flow ₹-58 Cr

Current Market Data

Current Price ₹1638.00
Exchange NSE
Last Updated Apr 27, 2026

Revenue Trend (₹ Cr)

Dec 2025 2,365
Jun 2025 2,104
Mar 2025 2,121
Sept 2025 2,273

Net Profit Trend (₹ Cr)

Dec 2025 231
Jun 2025 215
Mar 2025 197
Sept 2025 251

Operating Margin Trend (%)

Dec 2025 19.0%
Jun 2025 20.0%
Mar 2025 19.0%
Sept 2025 21.0%

EMCURE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Emcure Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025 		₹415,924.72 Cr 1733.5 14,875 3,125 +10.8% - 21.0% 133.3
Divis Laboratories
Sept 2025 		₹166,860.28 Cr 6477.0 2,860 689 +7.1% - 24.1% 249.4
Torrent Pharmaceuti…
Sept 2025 		₹139,344.76 Cr 4219.8 3,219 591 +11.3% - 18.4% 240.6
Dr Reddys Laborator…
Sept 2025 		₹109,930.83 Cr 1334.5 9,135 1,337 +1.1% - 14.6% 82.5
Lupin
Sept 2025 		₹104,941.69 Cr 2324.5 6,921 1,485 +23.2% - 21.5% 71.8
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores